Advertisement
U.S. markets closed
Advertisement

Bellicum Pharmaceuticals, Inc. (BLCM)

Other OTC - Other OTC Delayed Price. Currency in USD
0.2008+0.0008 (+0.40%)
At close: 03:14PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2000
Open0.2000
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range0.2000 - 0.2491
52 Week Range0.0600 - 1.5000
Volume11,815
Avg. Volume18,493
Market Cap1.951M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.7200
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLCM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BELLICUM PHARMACEUTICALS
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more